Table 5

Summary of most commonly reported outcomes measures at 12 weeks (or nearest point to). P values relate to active treatment versus placebo or reduced dose. * Indicates a statistical significant difference in favour of EWST treatment. Figures in parentheses are 95% confidence intervals. Where p-values were not provided, the values for mean and standard deviations [SD] are given, I indicates EWST group, II indicates placebo group. "Favours ESWT" indicates a better outcome for ESWT where neither of the previous details are provided.

Author

Morning/start up pain

Overall pain

Walking ability /activity related

Foot specific score

Pain at rest (100 mm VAS)

Pain on pressure

Night pain/evening pain

End point


Abt et al [21]

P = 0.016*

-

Favours ESWT

-

P = 0.01*

P = 0.26

P = 0.01*

19 weeks

Buch et al [27]

P = 0.0309

-

P = 0.7377

I. (49.1–71.5)

II.(32.9–55.9) AOFAS

-

Not significant

P < 0.4338

12 weeks

Buchbinder et al [10]

P = 0.92 (-12.7 – 13.1)

P = 0.99 (-10.3–11.5)

P = 0.0.72 (0.6–1.9)

P = 0.85 (-7.6–5.3) Maryland FS

-

-

-

12 weeks

Cosentino et al [33]

P < 0.0001*

-

P < 0.0001*

-

P < 0.0001*

-

-

12 weeks

Haake et al [11]

I mean = 4.0, SD = 3.2

II mean = 4.5, SD = 3.0

-

Favours ESWT

-

I mean = 2.4, SD = 2.6

II mean = 2.4, SD = 2.5

I mean = 4.0, SD = 3.2

II mean = 4.3, SD = 3.2

I mean = 1.5, SD = 2.4

II mean = 1.8, SD = 2.5

12 weeks

Krischek et al [22]

-

Favours ESWT

Favours ESWT

-

-

Favours ESWT

-

12 weeks

Ogden et al [28]

Favours ESWT

-

-

-

-

Favours ESWT

-

12 weeks

Rompe et al [32]

-

-

Favours ESWT

-

P < 0.0001*

P < 0.0001*

P < 0.0001*

12 weeks

Rompe et al [30]

Favours ESWT

Favours ESWT

P < 0.0001*

-

P < 0.05*

P < 0.0001*

P < 0.05*

12 weeks

Rompe et al [31]

P = 0.0004*

-

-

P = 0.0025* AOFAS

-

-

-

26 weeks

Speed et al

P = 0.664 (0.656–1.271)

P = 0.246 (0.626–1.093)

-

-

-

-

P = 0.378 (0.620–1.166)

12 weeks


Thomson et al. BMC Musculoskeletal Disorders 2005 6:19   doi:10.1186/1471-2474-6-19

Open Data